

Clinical Development in Alzheimer's Disease and Other Dementias

Rooted in Science, Focused on Quality, Based on Operational Excellence

Worldwide Clinical Trials has long been involved in advancing treatment options for people with Alzheimer's disease (AD) and other dementias. Our experience spans all main drug classes studied in AD, and in partnership with innovative companies and the support of patients and their families, we are helping to shape the future of AD and related dementia research, including dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD).

We are proud to have applied our years of experience to the conduct of a global Phase III study, which led to the first full approval of an anti-amyloid disease-modifying agent for early AD. Our focus on clinical methodology and data integrity culminated in statistically significant results that offer hope to people with AD and their families.



Read more about how we supported this sponsor and set a precedent for AD trial delivery →



122
Studies
(Full services and other)



3000+
Sites




1200+
Investigators



35+
Countries
(All Regions)



20,000+
Participants



*Excludes strategic consulting projects (18)

Our Approach



Exceptional scientific expertise and consultative approach



Strong site relationships and recruitment performance



Industry-leading rater training and clinical outcome assessment quality assurance



Imaging and bioanalytical lab vendor partnerships

Worldwide excels in the global conduct of advanced therapeutics development.

Partner with Worldwide Clinical Trials

Worldwide Clinical Trials (Worldwide) is a leading full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality.

Let's talk about how we can support your next program. [Contact us.](#)